Scarica l'app Stockscreener
134.68
2.35%
-3.24
Dopo l'orario di chiusura:
134.80
0.12
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$137.92
Aprire:
$136.74
Volume 24 ore:
1.87M
Relative Volume:
1.16
Capitalizzazione di mercato:
$9.34B
Reddito:
$2.90B
Utile/perdita netta:
$302.80M
Rapporto P/E:
31.35
EPS:
4.2965
Flusso di cassa netto:
$387.80M
1 W Prestazione:
-10.56%
1M Prestazione:
-5.72%
6M Prestazione:
-43.47%
1 anno Prestazione:
-60.11%
Intervallo 1D:
$134.11
$138.66
Intervallo di 1 settimana:
$134.11
$150.56
Portata 52W:
$126.40
$354.88
Insulet Corp Stock (PODD) Company Profile
Nome
Insulet Corp
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
134.68 | 9.57B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Downgrade | Citigroup | Buy → Neutral |
| 2026-01-27 | Ripresa | TD Cowen | Hold |
| 2026-01-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corp Borsa (PODD) Ultime notizie
Insulet Corp (PODD) Shares Fall 3.1% -- What GF Score of 77 Tells Investors - GuruFocus
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet at Wells Fargo conference: guidance cut meets long-term optimism - Investing.com
Is Insulet Corp (PODD) a Bargain After 3.5% Drop? GF Value Says Undervalued - GuruFocus
Grabar Law probes Bloom Energy, Cogent, Insulet, Primoris for fiduciary breaches - scanx.trade
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Why Insulet (PODD) Stock Is Down Today - Quiver Quantitative
State offers record $40M package to keep medical device company in Mass. - NBC Boston
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now? - Yahoo Finance
Artisan Sold Insulet (PODD) Due to Competition Concerns - Yahoo Finance
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report? - Yahoo Finance
Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks - Yahoo Finance
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds - Yahoo Finance
Is Insulet (PODD) Undervalued On Lawsuit And Device Correction Risks? - Yahoo Finance
Important Notice to Long-Term Shareholders of Hub Group, - GlobeNewswire
Insulet Corporation: Strong Growth Meets A New Execution Problem (NASDAQ:PODD) - Seeking Alpha
MONDAY PODD INVESTOR DEADLINE: Insulet Corporation - globenewswire.com
PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit with SBS Law - GlobeNewswire
PODD INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire
PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class ActionContact Levi & Korsinsky - PR Newswire
Important Notice to Long-Term Shareholders of ARS - globenewswire.com
1 WEEK INVESTOR DEADLINE: Insulet Corporation Investors with Substantial Losses Have Opportunity to Lead the Insulet Class Action Lawsuit Before August 31, 2026 DeadlinePODD - TMX Newsfile
PODD Deadline Alert: Levi & Korsinsky Reminds Insulet - GlobeNewswire
Insulet CEO Ashley McEvoy buys $162,217 in company stock By Investing.com - Investing.com Nigeria
Insulet CEO Ashley McEvoy buys $162,217 in company stock - Investing.com
Mitsubishi UFJ Asset Management Co. Ltd. Makes New Investment in Insulet Corporation $PODD - MarketBeat
Deutsche Bank AG Purchases Shares of 335,980 Insulet Corporation $PODD - MarketBeat
PODD INVESTOR DEADLINE: Insulet Corporation Investors with Substantial Losses Have Opportunity to Lead the Insulet Class Action Lawsuit Before August 31, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - The AI Journal
Insulet Corp (PODD) Shares Fall 3.0% -- What GF Score of 81 Tells Investors - GuruFocus
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
PODD UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - TMX Newsfile
14,672 Shares in Insulet Corporation $PODD Purchased by Aurora Investment Counsel - MarketBeat
Insulet Corporation Stockholders May Be Eligible to Lead the Class Action Against PODD; Contact Robbins LLP Before the August 31, 2026 Deadline for Information - The Globe and Mail
Is It Too Late to Buy Insulet Corp (PODD) After 6.0% Rally? GF V - GuruFocus
Insulet (PODD) Stock Slumps As Earnings Beat Collides With Guidance Reset - StocksToTrade
Insulet (NASDAQ:PODD) Shares Up 4.9%What's Next? - MarketBeat
PODD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Insulet (PODD) Investors of Securities Class Action Lawsuit Deadline on August 31, 2026 - TMX Newsfile
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Insulet Corporation (PODD) - TMX Newsfile
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
AUGUST 31, 2026 INVESTOR DEADLINE: Insulet Corporation - GlobeNewswire
2 WEEK INVESTOR DEADLINE: Insulet Corporation Investors with Substantial Losses Have Opportunity to Lead the Insulet Class Action Lawsuit Before August 31, 2026 DeadlinePODD - PR Newswire
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Insulet (PODD) Q2 2026 Earnings Call Transcript - AOL.com
OneDigital Investment Advisors LLC Buys Shares of 44,275 Insulet Corporation $PODD - MarketBeat
GSA Capital Partners LLP Acquires New Holdings in Insulet Corporation $PODD - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
PODD FINAL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Insulet Corporation ... - Caledonian Record
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
5 Must-Read Analyst Questions From Insulet’s Q2 Earnings Call - Yahoo Finance
Insulet Corp Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.29%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):